e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Airways disease comorbidities and general aspects
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice
M. L. Zaremba, K. Elliott, A. Redford, S. Ali, N. Shah, S. Reddy (Port Huron, United States Of America)
Source:
Annual Congress 2011 - Airways disease comorbidities and general aspects
Session:
Airways disease comorbidities and general aspects
Session type:
Thematic Poster Session
Number:
4000
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. L. Zaremba, K. Elliott, A. Redford, S. Ali, N. Shah, S. Reddy (Port Huron, United States Of America). The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice. Eur Respir J 2011; 38: Suppl. 55, 4000
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Validity of serum surfactant protein D as a lung-specific biomarker in monitoring asthma, chronic obstructive pulmonary disease and chronic bronchitis in Lebanese patients: Preliminary results
Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases
Year: 2012
Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study
Source: Annual Congress 2007 - Asthma subphenotypes
Year: 2007
Similarities and differences between asthma and chronic obstructive pulmonary disease: treatment and early outcomes
Source: Eur Respir J 2003; 21: 30S-35S
Year: 2003
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Asthma control or asthma severity
Year: 2008
Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly
Source: Eur Respir J 2003; 21: 3S-9S
Year: 2003
Is high level of IgE an additional problem in smoking patients with severe and very severe chronic obstructive pulmonary disease (COPD)?
Source: Annual Congress 2012 - COPD: epidemiology and varia
Year: 2012
Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 903-908
Year: 2001
The future of disease monitoring and management: the homework for clinical researchers
Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not?
Year: 2005
Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome?
Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not?
Year: 2005
Detection of asthma and chronic obstructive pulmonary disease in primary care
Source: Eur Respir J 2003; 21: 16S-22S
Year: 2003
Detection of antibody response against influenza vaccine in patients with chronic obstructive pulmonary disease (COPD) by quantitative ELISA and evalution of clinical findings
Source: Annual Congress 2009 - Viruses and respiratory infections: prevalence and mechanisms of infection
Year: 2009
Drug prescribing and burden of asthma and chronic obstructive pulmonary disease (COPD): a study from Italian general practitioners
Source: Eur Respir J 2005; 26: Suppl. 49, 672s
Year: 2005
Delivery of asthma and chronic obstructive pulmonary disease (COPD) services in UK primary care: nurses‘ roles and responsibilities
Source: Annual Congress 2007 - Nurses' involvement in the follow-up of patients with COPD and lung cancer
Year: 2007
Why is it important to consider (sub)phenotypes of asthma and COPD?
Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not?
Year: 2005
Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD
Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers
Year: 2006
Adherence to national (UK) respiratory guidelines in general practice
Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care
Year: 2007
The role of inflammatory biomarkers and health related quality of life questionnaires in distinction of exacerbation and stable chronic obstructive pulmonary diseases
Source: International Congress 2014 – Markers
Year: 2014
Are current treatment recommendations suited to elderly patients with asthma or COPD?
Source: Eur Respir Mon; 2009: 43: 267–285
Year: 2009
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept